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ABSTRACT
OBJECTIVE
To assess the impact of COVID-19 on neurovascular
research and deal with the challenges imposed by the
pandemic.
Methods A survey-based study focused on randomized
controlled trials (RCTs) and single-arm studies for acute
ischemic stroke and cerebral aneurysms was developed
by a group of senior neurointerventionalists and sent
to sites identified through the clinical trials website
(https://clinicaltrials.gov/), study sponsors, and physician
investigators.
Results The survey was sent to 101 institutions, with
65 responding (64%). Stroke RCTs were being conducted
at 40 (62%) sites, aneurysm RCTs at 22 (34%) sites,
stroke single-arm studies at 37 (57%) sites, and
aneurysm single-arm studies at 43 (66%) sites. Following
COVID-19, enrollment was suspended at 51 (78%)
sites—completely at 21 (32%) and partially at 30 (46%)
sites. Missed trial-related clinics and imaging follow-ups
and protocol deviations were reported by 27 (42%),
24 (37%), and 27 (42%) sites, respectively. Negative
reimbursements were reported at 17 (26%) sites. The
majority of sites, 49 (75%), had put new trials on hold.
Of the coordinators, 41 (63%) worked from home and
20 (31%) reported a personal financial impact. Remote
consent was possible for some studies at 34 (52%)
sites and for all studies at 5 (8%) sites. At sites with
suspended trials (n=51), endovascular treatment without
enrollment occurred at 31 (61%) sites for stroke and 23
(45%) sites for aneurysms. A total of 277 patients with
acute ischemic stroke and 184 with cerebral aneurysms
were treated without consideration for trial enrollment.
Conclusion Widespread disruption of
neuroendovascular trials occurred because of COVID-19.
As sites resume clinical research, steps to mitigate similar
challenges in the future should be considered.

accommodate patients with COVID-19 have been
widely adopted. Societal guidelines containing overlapping recommendations, based on evidence in the
literature and expert consensus, were published to
codify this.1–3 By contrast, the impact of COVID-19
on clinical research efforts has been less clear.
The Food and Drug Administration (FDA)
published its guidance on the 'Conduct Of Clinical Trials Of Medical Products During COVID-19
Pandemic' for the industry, investigators, and institutional review boards in March 2020 and updated
these on April 2, 2020 (https://www.fda.gov/media/
136238/download). This guidance is expected to
remain in effect until the public health emergency
related to the pandemic is lifted by the Department
of Health and Human Services. The FDA document
is comprehensive and recognizes the challenges
due to quarantines, suspension of trials, and interruption of supply chains. It also recognizes that
protocol deviations are likely and that trial modifications may be required. Similar guidelines were
issued by the European Medicines Agency on the
management of clinical trials during the COVID-19
pandemic on April 28, 2020 (https://ec.europa.eu/
health/sites/health/files/files/eudralex/vol-10/guid
anceclinicaltrials_covid19_en.pdf).
Disruption of clinical research infrastructure has
implications for patient enrollment, study timing,
sponsorship, and advances in clinical care and
disease understanding. At the time of writing, fears
of resurgent or re-emergent disease remain prominent.4 The impetus of this study was clinical trial
suspension and challenges in patient monitoring
experienced by several physician investigators and
enrolling sites. This led to formulation of a hypothesis and study design which aimed to evaluate the
impact of COVID-19 on neurovascular research
studies and had a goal of better understanding the
implications for existing and future trials.

INTRODUCTION

METHODS

The neurovascular community has had to date a
relatively homogeneous response to the COVID-19
pandemic with regards to clinical care. Measures
including elective case suspension and modifications
for emergency treatment and safety procedures to

Institutional review board approval was not
obtained as the survey did not involve study of
human subjects. A survey writing group committee,
comprising 12 neurointerventional physicians (four
neuroradiologists, five neurosurgeons, and three
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neurologists) each with 10 or more years of experience in clinical
practice, was assembled. All were involved in neurovascular clinical trials as site principal investigators and six were leading clinical trials as national principal investigators. The writing group
was tasked with composing a concise survey, limited to fewer
than 20 questions, to be completed by institutional research
coordinators to explore the effect of COVID-19 on neurointerventional research and clinical trials (full survey can be found in
online supplementary materials A). The survey focused on endovascular trials for acute ischemic stroke and cerebral aneurysms,
including both randomized clinical trials (RCTs) and single-arm
studies. The specific trial names or study sponsors were not
recorded to protect confidentiality. The site name was only
logged to assure one response from each site. No compensation
was offered to participants. No requests to complete the survey
were placed on public social media platforms. The questions
were intended to explore key aspects of managing clinical trials
in a restricted environment as imposed by the pandemic. These
were identified by the writing group and fell into four categories: general disruption caused by trial suspensions and missed
opportunities of enrollment, compromised trial quality due to
inability of timely clinical and imaging follow-up, inability to
enroll neurologically debilitated patients because legally authorized representatives were not at hand for face to face consent
and dated remote consent procedures did not apply and, finally,
personal effect of compensation or working conditions on study
staff. The question about remote consent related to existing operating procedures for ongoing trials. The suspension of clinical
trials was divided into partial or complete suspension based on
whether some or all neuroendovascular trials were suspended.
In cases of partial suspension, the question did not give details
of the criteria for suspending some trials and not others. The
survey also did not seek information on the size of the program,
case volume, or association with a research consortium. This was
partly to ensure that the brevity of the survey was maintained,
and partly to maintain broad applicability of the survey regardless of program size, academic affiliation, or geographic location. The final questionnaire was also reviewed by three industry
sponsors of clinical trials, two of which agreed to disclose their
names (Stryker Neurovascular; Fremont, California, USA and
Cerenovus; Miami, Florida, USA).
The survey sample was identified by creating a list of participants from the federal repository website (clinicaltrials.gov).
The website allows combinations of search terms to identify
clinical trials. The search terms used included 'stroke', 'thrombectomy', and 'brain aneurysms' with the geographic localizer of

clinical trials in the 'United States'. The results were filtered for
recruiting trials. The website provided contact details for each
study. In a separate process, various study sponsors and principal investigators of ongoing clinical trials were approached
by members of the writing group and asked to provide lists of
participating sites. The accumulated sites were cross referenced
with the list generated from clinicaltrials.gov to eliminate duplicates and when site information was missing, physician investigators localized by state were identified and invited individually
through the Society of Neurointerventional Surgery senior
physician membership (https://www.snisonline.org/). The final
sample resulted in a total of 101 institutions identified for
potential participation.
The finalized survey was prepared on Qualtrics (https://www.
qualtrics.
com) using an institutional license. The survey was
distributed to the identified sites by email and was open for a
4-week period from April 21, 2020 to May 21, 2020. To boost the
response rate, a digital link to the survey and a printable version
(PDF, Word document) were emailed to the physician investigators and study coordinators midway through the 4-week period
as a prompt. Surveys were completed voluntarily by a research
coordinator at each institution with the help of the physician
investigator as required. Each center was permitted only one
response. The survey is presented as descriptive statistics.

RESULTS
The survey was sent to study coordinators at 101 institutions
with 65 responding (64%). All responding sites were actively
involved in neurovascular trials before the COVID-19 pandemic.
Of the returned forms, the only missing responses related to
entry of the date of clinical trial suspension (if applicable). An
evaluation of endovascular studies showed that a majority of
sites were conducting stroke-related RCTs or single-arm studies.
arm aneurysm trials
Most sites were also conducting single-
while a minority were participating in aneurysm-related RCTs
(figure 1A).
During the pandemic, the majority of the sites either partially
or completely suspended enrollment in clinical trials (figure 1B),
with the suspension occurring between the middle to the end of
March 2020. There was no correlation between site trial suspension and geographic location or academic affiliation. Suspension of sites by state showed a heterogeneity of response, with
different sites in same state having different responses (figure 2).
No correlation was found between trial suspension and the
intensity of the pandemic.

Figure 1 (A) The randomized controlled trials (RCTs) and single arm studies for stroke and aneurysms being conducted at the responding sites
(n=65) prior to COVID-19. (B) clinical trial suspension at the responding sites during the pandemic.
2 of 6

Rai AT, et al. J NeuroIntervent Surg 2020;12:831–835. doi:10.1136/neurintsurg-2020-016502

Standards

Figure 2 A chart of trial suspensions by state. The width of the bar for a given state correlates to the number of sites responding from that state.
The wider the bar, the more the sites responding from that state. These are depicted in ascending order from left to right.
Endovascular stroke care continued in sites where enrollment
had been suspended (n=51), and most of these sites treated
patients with acute ischemic stroke without enrollment. Almost
half of the sites treated patients with an aneurysm (figure 3A).
A total of 277 patients with endovascular stroke and 184 with
endovascular aneurysm were treated without consideration for
enrollment following suspension of clinical trials. Effects were
also observed on patients already enrolled in trials. Forty-two
percent of sites missed clinical follow-up visits, and 37% missed
imaging follow-
up. Under half of the sites (42%) reported
protocol deviations because of the pandemic and a quarter
reported loss of reimbursements possibly due to delayed or
missed milestones or inability to enroll patients (figure 3B).
Almost all (61/65, 94%) sites had developed alternative mechanisms such as telemedicine for clinical visits.
Most of the sites had received institutional review board guidance for the conduct of clinical trials (n=57, 88%) and most had
received guidance from sponsors for either all (n=31, 48%) or
some (n=30, 46%) of the clinical trials. Over half of the sites
allowed electronic or phone consent for enrollment (figure 4).
There were widespread challenges for study staff, with the
majority of the study coordinators working from home (n=41,
63%) or a combination of home and office (n=18, 28%) and
almost a third (n=20, 31%) reporting being personally affected
by the pandemic either due to loss of pay, paid time off, or loss
of benefits. The majority of the sites (n=49, 75%) had placed
new trials on hold, with the number of postponed trials per site
ranging from one to seven. Two sites reported a diagnosis of
COVID-19 among the enrolled patients.

DISCUSSION
This study identified widespread disruptions to neurovascular
clinical trial networks, most notably due to a suspension or postponement of trial enrollment, interruptions in scheduled patient
follow-up, and challenges with study staff routines. Cessation of
ongoing trials was nearly uniform, which may have downstream
effects on trial validity and solvency. Understanding the effect
of COVID-19 on clinical trials during the early months of the
pandemic is especially important given the uncertainty about the
future and potential need for subsequent lockdowns should widespread infection recur after resumption of elective procedures and
relaxation of social distancing measures. One previous letter has
been published, documenting decreased enrollment related to the
pandemic in cancer-related clinical trials,5 and another systematic
review on cancer research during COVID-19.6 The Federation of
Italian Cooperative Oncology group issued a brief commentary
and practice indications for drug studies.7 Other publications have
included clinical trials for Alzheimer’s research,8 and a review
for guidance in head and neck research.9 At the time of writing,
no published studies measuring the comprehensive impact of
COVID-19 on research are available, and while this study focuses
specifically on neurovascular research and trials, disruptions
captured may well be generalizable to United States clinical trials
in other medical specialties.
A prominent source of disruption identified by this survey was
the complete or partial suspension of trial enrollment. Many
sites with suspended enrollment treated potentially eligible
patients with stroke and aneurysm. A total of 277 patients with

Figure 3 (A) Sites with partial or complete suspension (n=51) reporting endovascular treatment of patients with stroke or an aneurysm without
enrollment. (B) Sites reporting missed clinical or imaging follow-up visits, protocol deviations, and loss of reimbursements. AIS, acute ischemic stroke.
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Figure 4 Remote consent policies adopted at responding sites.
stroke and 184 with an aneurysm reportedly underwent endovascular therapy at these sites during the period in which the
survey was conducted and thus could not be considered for
enrollment owing to the suspension of clinical research. In view
of the number of sites that did not respond to the survey, this
number may be even higher. Unlike the 'clinical deficit', which
is expected to be gradually overcome by returning case volume
and case rescheduling, no similar option exists for research
enrollment deficits. The most likely means of compensating for
missed enrollments is to extend trial enrollment timelines. Such
extension has implications for funding, compounded by potential contraction of funding following the wider economic impact
of the global pandemic.
Beyond enrollment alone, trial quality was compromised.
Many patients missed clinical and imaging follow-
up milestones, and many sites reported protocol deviations due to the
pandemic. These may increase as pandemic effects continue and
could affect the veracity of overall trial data. Site trial infrastructure will have to adjust to new realities of reduced funding
for many centers, with just over a quarter reporting a negative
impact on reimbursements.
Human trial expertise has also been affected by the COVID-19
pandemic. Sites could experience reassignment, furloughing, or
third of responding
termination of study coordinators. One-
coordinators reported a direct personal effect through loss of
pay, time off, or benefits. As operations gradually return, this
human expertise may need to be rebuilt. Trialists and staff will
also need ongoing protection from potential infectious exposures.10 Failure to do so could affect a site’s ability to perform
existing and future trials unless alternative mechanisms are
developed.
As clinical research activities resume with lifting of mandated
lockdowns, this survey highlights several opportunities to update
the conduct of clinical trials in accordance with the virtual care
revolution brought about by the COVID-19 pandemic.11 12
In this survey, 40% of the responding sites did not have any
4 of 6

protocols in place for remote consent. Challenges to the traditional consent process could persist into the foreseeable future
as hospital visitor restrictions are likely to remain in place for
some time. Study sponsors, local institutional review boards, and
federal authorities regulating these trials will have to demonstrate creativity in modernizing these procedures. Harnessing
emerging virtual technologies that allow for face-to-face interactions with legally authorized representatives, electronic exchange
of documents, and digital signatures, represents a clear opportunity. It is possible to comply with the ethical principles governing
informed consent while updating these procedures to meet the
current and future needs of operating with restricted visits.13
In the recovery phase there are calls in both public and
medical circles for our healthcare infrastructure to focus on
broadly improving our approaches, not simply returning to
the prior state of normalcy.14 For acute trials in particular this
could have broad positive implications for enrollment. Further,
there are opportunities to enhance virtual capabilities to conduct
person monitoring and
trials, with reduced reliance on in-
reporting forms. Based on existing data about telehealth,15 this
may expand the trial footprint, decrease trial costs, and potentially increase trial efficiency. Trial reorganization into adaptive
designs like platform trials may allow us to respond more rapidly
to design changes and randomize more effectively as new questions arise.16 Early efforts are underway to develop a neurovascular platform trial infrastructure, and this should remain a focus
for the neurointerventional community.
Another important consideration is how to handle potential
trial candidates regarding COVID-19 exposure. In this survey, a
small number (two sites) reported a positive COVID-19 diagnosis
in enrolled patients. There is current uncertainty about how to
process patients with COVID-19 in neurovascular trials or whether
to screen based on symptoms or exposures. The direct effect of
SARS-CoV-2 on cerebrovascular disease remains largely unknown,
but early evidence suggests endothelial involvement17 and a range
of syndromes18–20 that could confound the natural history of the
disease or treatment response. This may be particularly relevant for
studies of cerebrovascular conditions where patient outcomes may
be directly influenced apart from the interventions being studied.
How patients with COVID-19 should be handled by trials that
are not focused on that disease specifically, is unknown. Testing
all potential enrollees for COVID-19 and excluding all positive
patients a priori seems reasonable, but this could result in unnecessary delays in enrollment or exclusion of patients who are COVID
false positive or who have recovered from COVID. This larger
question will probably be answered as we learn more about the
virus. As more data are collected on the impact of the pandemic on
clinical trials it may be possible to crystallize strategies for operating
in a restrictive environment due to lingering concerns of outbreaks.

Limitations

This study has several important limitations. As a survey study,
this study is subject to the inherent limitations of survey methodology, including recall and selection bias. The potential for
selection bias is strong as those most affected by the pandemic
may be more likely to complete the surveys. Additionally, centers
with furloughed or terminated coordinators were unable to
provide responses. A number of potentially important research
or practice-specific questions, such as region or the prevalence of
COVID-19 in the population, were not included in the survey by
the writing group to improve participation rates. Questions were
intentionally generated to assess a broad overview of research as
opposed to specifically focus on individual trial statistics. The
survey questions were purposely kept under 20, and therefore
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details that might have been helpful in further exploring some
responses were not obtained. For example, the criteria for
choosing to keep some trials open and others suspended are not
known. Likewise, details of the causes of loss of trial-related
reimbursements were not obtained. Additionally, implications
based research, or for
for neurovascular basic or laboratory-
research in other domains, were similarly not assessed. The
questions used were not previously validated and were designed
specifically for the NI research coordinators involved in clinical
trials, which may limit their generalizability to other specialties
and make comparison with data from other surveys challenging.
Lastly, since this type of pandemic has never occurred in modern
history, there is no previously developed, validated survey instrument to study the effects of a global pandemic on research.

CONCLUSION

This is the first study comprehensively evaluating the effect of
COVID-19 on clinical trials. Respondents indicated widespread
disruption of neurovascular clinical research and research infrastructure during the COVID-19 pandemic. It has also revealed
opportunities for increased infrastructural strength and pliability,
including the increased use of virtual access for consent and
up, and the benefits of platform trial design at times
follow-
when flexibility and responsiveness are key advantages. Many
questions remain to be answered, including how we should
incorporate COVID-19 screening into trial criteria. It should be
expected that disruptions due to COVID-19 will continue, based
on expert predictions of the disease course. Trial conduct in this
restrictive environment will need to evolve. Decisions about how
to maintain enrollment during the current pandemic and in the
event of future similar disruptions21 must be prioritized.
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